For patients with obesity and high cardiometabolic risk whose VCTE liver stiffness is borderline (about 8–10 kPa), what is your preferred tie-breaker to justify initiating MASH-directed pharmacotherapy: ELF, a second serum fibrosis panel, repeat VCTE after weight stability, or MR-based fibrosis assessment when available?